Theragenics signs agreement with Core Oncology for distribution of TheraSeed palladium-103 brachytherapy seeds

Jan 13 2010

Theragenics Corporation (NYSE: TGX), a medical device company serving the surgical products and prostate cancer treatment markets, today announced that it has signed an agreement with Core Oncology, Inc. for the distribution of TheraSeed^® palladium-103 brachytherapy seeds. Under the terms of the agreement, Theragenics will be the exclusive palladium-103 seed supplier to Core for the treatment of prostate cancer in the U.S. and Canada. The term of the agreement is through November 30, 2011, and is automatically extended for additional one-year terms unless terminated by either party upon prior written notice.

“As one of the largest palladium-103 seed distributors in the U.S. and an innovator in delivering total brachytherapy solutions to their customers, Core is a recognized leader in the industry.”

“We are delighted to be partnering with Core as their exclusive supplier of palladium-103 seeds for prostate cancer treatment in the U.S. and Canada,” stated M. Christine Jacobs, Chairman and CEO of Theragenics. “As one of the largest palladium-103 seed distributors in the U.S. and an innovator in delivering total brachytherapy solutions to their customers, Core is a recognized leader in the industry.”

“TheraSeed^® provides us with the industry’s leading palladium seed to compliment our industry leading iodine-125 product, ProstaSeed^®,” stated Travis Gay, CEO and President of Core Oncology. “Theragenics is a recognized leader in brachytherapy and our new partnership should further Core’s goal of providing high quality and innovative products to our customers.”